This study will evaluate the survival of non-small cell lung cancer (wild-type EGFR) participants treated with Tarceva after at least one failed chemotherapy treatment, and the impact of prior chemotherapy treatments.
Study Type
OBSERVATIONAL
Enrollment
33
Erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
Unnamed facility
Bucharest, Romania
Survival Rate at Month 6
Time frame: Month 6
Survival Rate at Month 12
Time frame: Month 12
Progression Free Survival (PFS) at Month 6
PFS is defined as the time from inclusion in the study to the disease progression or death whichever occurs first. Disease progression was determined according to local treatment guidelines.
Time frame: From inclusion up to disease progression or death whichever occurs first (up to 6 months)
Progression Free Survival (PFS) at Month 12
PFS is defined as the time from inclusion in the study to the disease progression or death whichever occurs first. Disease progression was determined according to local treatment guidelines.
Time frame: From inclusion up to disease progression or death whichever occurs first (up to 12 months)
Overall Survival (OS)
OS is defined as time from first administration of study drug until death from any cause.
Time frame: Up to 12 months
Percentage of Participants With Adverse Events (AEs)
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Up to 12 months
Overall Survival According to Prior Chemotherapy Treatment.
Prior chemotherapy treatment is presented as reported by the investigators.
Time frame: Up to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.